Printer Friendly

MEDTRONIC INFORMS PCD CLINICAL INVESTIGATORS OF ANIMAL STUDY OBSERVATIONS

 MEDTRONIC INFORMS PCD CLINICAL INVESTIGATORS
 OF ANIMAL STUDY OBSERVATIONS
 MINNEAPOLIS, July 20 /PRNewswire/ -- Medtronic, Inc. (NYSE: MDT) said today that it had informed clinical investigators of its PCD system about new observations from animal studies.
 While noting that the animal data included no evidence of a clinical risk to human patients, the company said two animals implanted with the device for more than two years had presented with sarcomas. Medtronic told physicians that the cause of the intrathoracic tumors in the two animals was most probably a phenomenon called "solid-state tumorigenesis" occasionally seen in animals with implants of large surface area matece.
 The company's clinical evaluations and post-market release studies, which are continuing, show no evidence of these tumors in patients with the PCD system. Similarly, the scientific literature shows no indication of tumorigenisis related to implantable cardioverter defibrillators in humans. Implants of the PCD began in 1989. Medtronic told physicians that testing has ruled out any material- or manufacturing-related factors.
 The company has notified the U.S. Food and Drug Administration which is considering the device for commercial release.
 Medtronic, Inc., headquartered in Minneapolis, is a leading developer and manufacturer of biomedical devices for improving cardiovascular and neurological health.
 -0- 7/20/92
 /CONTACT: Dale Beumer (Investor), 612-574-3038, or Dick Reid (Media), 612-574-3052, both of Medtronic/
 (MDT) CO: Medtronic, Inc. ST: Minnesota IN: MTC SU:


AL -- MN010 -- 0803 07/20/92 14:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1992
Words:235
Previous Article:COOPER TIRE REPORTS RECORD SECOND QUARTER
Next Article:GOVERNMENT TECHNOLOGY SERVICES ANNOUNCES PRELIMINARY SECOND QUARTER RESULTS
Topics:


Related Articles
PANEL CONSIDERATION DOUBTFUL FOR MEDTRONIC PCD DEVICE AT NOVEMBER MEETING
PCD LEAD SYSTEM REQUIRING NO MAJOR CHEST SURGERY IS RELEASED BY MEDTRONIC IN EUROPE
FDA ADVISORY PANEL TO CONSIDER MEDTRONIC PCD DEVICE AT FEBRUARY MEETING
MEDTRONIC INFORMS PCD CLINICAL INVESTIGATORS OF ANIMAL STUDY OBSERVATIONS
FDA ADVISORY PANEL TO CONSIDER MEDTRONIC TRANSVENE LEADS AT MEETING IN AUGUST
FDA ADVISORY PANEL RECOMMENDS APPROVAL OF LESS-INVASIVE LEADS FOR PCD SYSTEM
FDA APPROVES U.S. CLINICAL EVALUATION OF NEW MEDTRONIC DEVICE FOR HEARTS THAT BEAT TOO FAST
MEDTRONIC ANNOUNCES FIRST U.S. IMPLANT OF NEW, SIMPLER DEVICE FOR HEARTS THAT BEAT TOO FAST
MEDTRONIC ANNOUNCES FIRST U.S. IMPLANT OF NEW, SIMPLER DEVICE FOR HEARTS THAT BEAT TOO FAST
MEDTRONIC ANNOUNCES FIRST U.S. IMPLANT OF NEW, SIMPLER DEVICE FOR HEARTS THAT BEAT TOO FAST

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters